SQZ Biotechnologies is a clinical-stage biotechnology company developing cell therapies for patients with cancer, infectious diseases and other serious conditions. Co. uses its proprietary technology, Cell Squeeze, to squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Co. is developing three oncology therapeutic candidates, which include: SQZ® Antigen Presenting Cell, SQZ® Enhanced APC and SQZ® Activating Antigen Carrier. Co. is also developing its SQZ® Tolerizing Antigen Carrier platform with the aim to treat autoimmune diseases by inducing antigen-specific immune tolerance. The SQZ stock yearly return is shown above.
The yearly return on the SQZ stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SQZ annual return calculation with any dividends reinvested as applicable (on ex-dates).
|